To also assess the efficacy of SHIP1 inhibition on human CLL in vivo, we treated NOD/SCIDcγ−/− (NSG) mice xenografted with primary patient-derived CLL cells with the SHIP1-specific inhibitor 3AC in vivo (treatment schedule shown in Supplementary Fig. 3c). This evidence concerns the gene INPP5D and B-cell chronic lymphocytic leukemia.